PIONEERING A NEW WAVE OF ONCOLOGY TREATMENT
Immuno-oncology meets global science and big data
EXUMA Biotech is a clinical-stage biotechnology company discovering and developing cell and gene therapies for solid & liquid tumors.
Cell therapy has already delivered remarkable on-target responses to certain hematological malignancies through a complex manufacturing process. Through our tumor metabolism regulated (TMR) CAR-T and CAR-TaNK platforms, we are taking cellular therapies to the next step by harnessing the power of the immune system to target some of the most challenging solid tumor malignancies and building delivery platforms that may enable more patients to access cell & gene therapies in the future.
Next-generation autologous cell therapy
As part of our commitment to make cell therapies more accessible to earlier lines of therapy, we are developing best-in-class delivery solutions to address specific unmet needs in the cell therapy space.
CCT3: Our current centralized process is a fresh-in, frozen-out process on a fully electronic batch record system.
rPOC: Our next-generation, subcutaneous, chemotherapy-free technology platform is being developed to test the ability of CAR-modified cells to form in the body from a synthetic lymph node and mount a systemic anti-tumor response without the complications of chemotherapy. In the fight against cancer, our global teams are advancing this first of its kind autologous treatment that could make cell therapy a reality for more cancer patients.
Innovation is at the core of our global network
From West Palm Beach to Grand Cayman to Shanghai: We are integrated over 12 hours of time zones because cancer never sleeps, and neither does the data.
October 4, 2022
Dr. Sid Kerkar speaks with CGT Live about how EXUMA’s TaNK platforms aim to make CAR therapy safer and faster through novel lentivector engineering